Developer docs
API playgroundTry for free, no card

Search company profiles

Jasper Therapeutics

Full company profile

uuid00000a1

Namestring
Jasper Therapeutics
Legal namestring
Jasper Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Jasper Therapeutics is a clinical-stage biotechnology company headquartered in Redwood City, California, that develops briquilimab, a proprietary anti-KIT (CD117) monoclonal antibody designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Founded in 2019 and taken public via a 2021 SPAC merger with Notable on NASDAQ under ticker JSPR, the company's single-asset pipeline targets chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma — with discontinued programs in SCID and a paused asthma program following a July 2025 drug product contamination incident. Clinical data to date has shown meaningful efficacy signals, including 67% complete response at 12 weeks in the BEACON Phase 1b/2a study and significant eosinophil and lung function improvements in the ETESIAN Phase 1b asthma study, supporting a planned Phase 2b/3 CSU trial in 2H 2026.

The company's business model is that of a pre-revenue clinical-stage biotech: it generates no commercial revenue, has no product approvals, and funds operations exclusively through equity financings — most recently a $30M public offering in September 2025 at $2.43 per share, following a $50M raise in February 2024 and a $90M raise in January 2023. Cash reserves stood at $28.7M in Q4 2025 against a widened 2025 net loss of $75.8M. The go-to-market motion is entirely investor-relations-driven (conference participation, analyst coverage, IR webcasts), with no distribution or commercial infrastructure in place. Jasper is led by President and CEO Jeet Mahal (appointed January 2026) and Executive Chairperson Thomas Wiggans.

The company's near-term outlook is defined by financial distress and strategic uncertainty. In June 2026, the Board of Directors initiated a comprehensive strategic alternatives review evaluating potential sale of assets, licensing, collaborations, business combinations, or an orderly wind-down of operations, citing an imminent need for additional funding. With a single clinical-stage asset, a recent manufacturing quality failure, persistent operating losses, and limited runway, Jasper represents a high-risk, binary-outcome biotech investment where value depends on either successful strategic transaction execution or successful advancement of briquilimab into registrational trials.

Short descriptiontext

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a proprietary anti-KIT monoclonal antibody that depletes mast cells to treat chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma. The pre-revenue company is exploring strategic alternatives following a 2025 manufacturing contamination incident.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, anti-KIT monoclonal antibody, mast cell depletion therapy, chronic urticaria treatment, allergic asthma therapy
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
Product category
Clinical-stage biopharmaceuticals
Social media profiles2 records
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. The asset is being evaluated in clinical studies across chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and adult allergic asthma, with planned progression into a Phase 2b/3 trial in CSU in the second half of 2026. The company has no approved products and no commercial revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 67% of patients achieved complete response at 12 weeks in BEACON Phase 1b/2a study
+5 more records
Product overview1 text field

Jasper Therapeutics is a biotechnology company developing a single core product, briquilimab, which is a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases. The company's clinical pipeline focuses on evaluating briquilimab across multiple mast cell-driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. Jasper is conducting multiple clinical studies including the BEACON Phase 1b/2a study in CSU/CIndU and the ETESIAN Phase 1b study in asthma, with plans for a Phase 2b/3 trial in CSU in the second half of 2026.

Product and service1 record
1Briquilimab
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Celldex is developing barzolvolimab, an anti-KIT monoclonal antibody targeting mast cells, with clinical programs in CSU and other mast cell-driven diseases. It is the most directly comparable peer to Jasper given the shared anti-KIT mechanism and CSU focus.

2AB Science
TypeDirect peer
Description

AB Science is developing masitinib, a tyrosine kinase inhibitor that targets mast cell and c-Kit pathways, with clinical programs in mastocytosis and inflammatory diseases. Comparable as a mast cell pathway competitor in similar indications.

TypeEmerging player
Description

Evommune is a privately held biotech developing therapies for chronic inflammatory skin diseases including CSU and other mast cell-driven conditions. Relevant as an emerging competitor in overlapping dermatologic indications.

TypeBroad incumbent
Description

Novartis co-markets omalizumab (Xolair) with Genentech, the current standard of care in CSU. It is the incumbent competitor that any new anti-KIT therapy must displace or complement in refractory CSU.

TypeBroad incumbent
Description

Genentech co-markets omalizumab (Xolair) for CSU and chronic inducible urticaria and has deep immunology franchise overlap with briquilimab's target indications. Sets the efficacy and pricing benchmark for any new CSU biologic.

TypeBroad incumbent
Description

Sanofi markets Dupixent (dupilumab) for atopic dermatitis, asthma, and other type 2 inflammatory diseases, overlapping with Jasper's asthma and CSU development programs. A potential strategic acquirer or competitor in inflammatory disease markets.

TypeBroad incumbent
Description

AstraZeneca markets severe asthma biologics Fasenra (benralizumab, anti-IL-5R) and Tezspire (anti-TSLP), overlapping with Jasper's allergic asthma program. Represents both a competing therapy and a potential strategic acquirer in respiratory inflammation.

TypeBroad incumbent
Description

GSK markets Nucala (mepolizumab, anti-IL-5) for severe eosinophilic asthma and other inflammatory diseases, providing a comparator in the asthma space where briquilimab is being evaluated.

TypeEmerging player
Description

Blueprint Medicines is developing Ayvakit (avapritinib), a KIT inhibitor approved for systemic mastocytosis and PDGFRA-driven disorders. Comparable as a developer of KIT-pathway targeted therapies with adjacent mast cell indications.

10Allakos
TypeEmerging player
Description

Allakos is developing antibody therapies (e.g., lirentelimab) targeting mast cell and eosinophil pathways for inflammatory diseases including CSU. Relevant as a clinical-stage developer of mast cell-directed biologics in overlapping indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors32 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Jasper Therapeutics

Clinical-stage biopharmaceuticalsjaspertherapeutics.com

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a proprietary anti-KIT monoclonal antibody that depletes mast cells to treat chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma. The pre-revenue company is exploring strategic alternatives following a 2025 manufacturing contamination incident.

What Jasper Therapeutics does

Jasper Therapeutics is a clinical-stage biotechnology company headquartered in Redwood City, California, that develops briquilimab, a proprietary anti-KIT (CD117) monoclonal antibody designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Founded in 2019 and taken public via a 2021 SPAC merger with Notable on NASDAQ under ticker JSPR, the company's single-asset pipeline targets chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma — with discontinued programs in SCID and a paused asthma program following a July 2025 drug product contamination incident. Clinical data to date has shown meaningful efficacy signals, including 67% complete response at 12 weeks in the BEACON Phase 1b/2a study and significant eosinophil and lung function improvements in the ETESIAN Phase 1b asthma study, supporting a planned Phase 2b/3 CSU trial in 2H 2026.

The company's business model is that of a pre-revenue clinical-stage biotech: it generates no commercial revenue, has no product approvals, and funds operations exclusively through equity financings — most recently a $30M public offering in September 2025 at $2.43 per share, following a $50M raise in February 2024 and a $90M raise in January 2023. Cash reserves stood at $28.7M in Q4 2025 against a widened 2025 net loss of $75.8M. The go-to-market motion is entirely investor-relations-driven (conference participation, analyst coverage, IR webcasts), with no distribution or commercial infrastructure in place. Jasper is led by President and CEO Jeet Mahal (appointed January 2026) and Executive Chairperson Thomas Wiggans.

The company's near-term outlook is defined by financial distress and strategic uncertainty. In June 2026, the Board of Directors initiated a comprehensive strategic alternatives review evaluating potential sale of assets, licensing, collaborations, business combinations, or an orderly wind-down of operations, citing an imminent need for additional funding. With a single clinical-stage asset, a recent manufacturing quality failure, persistent operating losses, and limited runway, Jasper represents a high-risk, binary-outcome biotech investment where value depends on either successful strategic transaction execution or successful advancement of briquilimab into registrational trials.

Jasper Therapeutics firmographics

Firmographics
Name
Jasper Therapeutics
Legal name
Jasper Therapeutics, Inc.
Website
https://jaspertherapeutics.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a proprietary anti-KIT monoclonal antibody that depletes mast cells to treat chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma. The pre-revenue company is exploring strategic alternatives following a 2025 manufacturing contamination incident.
Ownership category
akta.pro rank

Where Jasper Therapeutics is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Jasper Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Marketing channels3 records

Jasper Therapeutics product offering

Product offering

Core offering

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. The asset is being evaluated in clinical studies across chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and adult allergic asthma, with planned progression into a Phase 2b/3 trial in CSU in the second half of 2026. The company has no approved products and no commercial revenue.

Product overview

Jasper Therapeutics is a biotechnology company developing a single core product, briquilimab, which is a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases. The company's clinical pipeline focuses on evaluating briquilimab across multiple mast cell-driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. Jasper is conducting multiple clinical studies including the BEACON Phase 1b/2a study in CSU/CIndU and the ETESIAN Phase 1b study in asthma, with plans for a Phase 2b/3 trial in CSU in the second half of 2026.

Differentiator

Problem solved

Functional benefit

Products and services

  • Briquilimab

Quantifiable outcome

  • 67% of patients achieved complete response at 12 weeks in BEACON Phase 1b/2a study
  • +5 more outcomes

Companies that use Jasper Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

Jasper Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Jasper Therapeutics partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Jasper Therapeutics competitors and assessment

Company assessment

Direct peers

  • Celldex Therapeutics: Celldex is developing barzolvolimab, an anti-KIT monoclonal antibody targeting mast cells, with clinical programs in CSU and other mast cell-driven diseases. It is the most directly comparable peer to Jasper given the shared anti-KIT mechanism and CSU focus.
  • AB Science: AB Science is developing masitinib, a tyrosine kinase inhibitor that targets mast cell and c-Kit pathways, with clinical programs in mastocytosis and inflammatory diseases. Comparable as a mast cell pathway competitor in similar indications.

Emerging players

  • Evommune: Evommune is a privately held biotech developing therapies for chronic inflammatory skin diseases including CSU and other mast cell-driven conditions. Relevant as an emerging competitor in overlapping dermatologic indications.
  • Blueprint Medicines: Blueprint Medicines is developing Ayvakit (avapritinib), a KIT inhibitor approved for systemic mastocytosis and PDGFRA-driven disorders. Comparable as a developer of KIT-pathway targeted therapies with adjacent mast cell indications.
  • Allakos: Allakos is developing antibody therapies (e.g., lirentelimab) targeting mast cell and eosinophil pathways for inflammatory diseases including CSU. Relevant as a clinical-stage developer of mast cell-directed biologics in overlapping indications.

Broad incumbents

  • Novartis: Novartis co-markets omalizumab (Xolair) with Genentech, the current standard of care in CSU. It is the incumbent competitor that any new anti-KIT therapy must displace or complement in refractory CSU.
  • Genentech (Roche): Genentech co-markets omalizumab (Xolair) for CSU and chronic inducible urticaria and has deep immunology franchise overlap with briquilimab's target indications. Sets the efficacy and pricing benchmark for any new CSU biologic.
  • Sanofi: Sanofi markets Dupixent (dupilumab) for atopic dermatitis, asthma, and other type 2 inflammatory diseases, overlapping with Jasper's asthma and CSU development programs. A potential strategic acquirer or competitor in inflammatory disease markets.
  • AstraZeneca: AstraZeneca markets severe asthma biologics Fasenra (benralizumab, anti-IL-5R) and Tezspire (anti-TSLP), overlapping with Jasper's allergic asthma program. Represents both a competing therapy and a potential strategic acquirer in respiratory inflammation.
  • GSK: GSK markets Nucala (mepolizumab, anti-IL-5) for severe eosinophilic asthma and other inflammatory diseases, providing a comparator in the asthma space where briquilimab is being evaluated.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Jasper Therapeutics social profiles

Digital presence

Jasper Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Jasper Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Jasper Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors32 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Jasper Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jasper Therapeutics

What does Jasper Therapeutics do?

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. The asset is being evaluated in clinical studies across chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and adult allergic asthma, with planned progression into a Phase 2b/3 trial in CSU in the second half of 2026. The company has no approved products and no commercial revenue.

Is Jasper Therapeutics a public or private company?

Jasper Therapeutics is a public company. It is classified as public and is currently operating.

When was Jasper Therapeutics founded?

Jasper Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is Jasper Therapeutics based?

Jasper Therapeutics is headquartered in Redwood City, United States, in the North America region.

Who are Jasper Therapeutics's main competitors?

Direct peers on record are Celldex Therapeutics and AB Science. Emerging players are Evommune, Blueprint Medicines and Allakos. Broad incumbents are Novartis, Genentech (Roche), Sanofi, AstraZeneca and GSK.

Does Jasper Therapeutics have an API?

No public API is recorded for Jasper Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comRodman & Renshaw reiterates Buy on Jasper Therapeutics stockRodman & Renshaw reiterated a Buy rating on Jasper Therapeutics, placing its price target under review after a 1-for-30 reverse stock split and planned model revisions. The firm cited completed enrollment in an IgA nephropathy trial and first patient dosing in an immune complex study, with a $135.3 million cash balance. The fourth-quarter 2026 Stage 1 interim IgAN readout for vensobafusp alfa is the key catalyst.Investing.comPiper Sandler cuts Jasper Therapeutics stock price target to $44Piper Sandler cut its price target on Jasper Therapeutics to $44 from $60, keeping an Overweight rating. The stock trades at $11.77, down 78% year-to-date, and Jasper reported Q3 2026 earnings. Its Phase 2 renal basket study is fully enrolled, with interim efficacy readout guided to year-end 2026.Quiver QuantitativeJASPER THERAPEUTICS ($JSPR) Releases Q3 2026 Earnings | JSPR Stock NewsJasper Therapeutics reported Q3 2026 earnings of -$13.97 per share, missing estimates by $10.95, while revenue of $8M beat estimates by $4.94M. Institutional investors added 23 shares and removed 29, with notable moves from Affinity Asset Advisors and Millennium Management. Analysts have issued buy ratings, including Outperform from William Blair and Overweight from Piper Sandler.Quiver QuantitativeJasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update on Renal Basket Study and Pipeline Progress | JSPR Stock NewsJasper Therapeutics reported Q3 2026 results, completing enrollment in its Phase 2 renal basket study for vensobafusp alfa in IgA nephropathy. The company held $135.3 million in cash and expects interim IgAN data in Q4 2026. It also initiated an expansion cohort for FSGS and enrolled the first IC-MPGN patient.TradingViewJasper Therapeutics: Renal pipeline advanced as Q3 results included a $129.5M acquisition-related chargeJasper Therapeutics reported a Q3 net loss of $144.5 million, including a $129.5 million acquisition-related charge, with $135.3 million in cash at quarter-end. The company advanced its renal pipeline, with interim IgAN data expected in Q4 2026.TradingViewJasper Therapeutics Reports $144.5 Million Q3 Net Loss, Advances Kidney Disease StudiesJasper Therapeutics reported a Q3 2026 net loss of $144.5 million, up from $18.7 million a year earlier, with revenue of $8.0 million. The loss included a $129.5 million charge for acquired in-process R&D. The company completed enrollment in its Phase 2 renal basket study and expects interim data in Q4 2026.American Banking and Market NewsJasper Therapeutics (NASDAQ:JSPR) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Jasper Therapeutics from a hold to a sell rating. The stock has a consensus rating of Hold with a $220 price target, and the company reported a loss of $3.00 per share for the quarter, beating estimates.Business & FinancialJasper Therapeutics, Inc. Announces Results Of The Offer To Purchase Relating To Its WarrantsJasper Therapeutics announced that 8,510,658 warrants were properly tendered, representing about 68.94% of outstanding warrants. The company expects to pay $2,757,453.19 in cash for these warrants, with payment made promptly.TradingViewJasper Therapeutics shares tank after announcing 1-for-30 reverse stock splitJasper Therapeutics shares fell over 14% on Wednesday after announcing a 1-for-30 reverse stock split effective November 6, 2026. The split will reduce outstanding shares from nearly 33.3 million to about 1.11 million.American Banking and Market NewsJasper Therapeutics (NASDAQ:JSPR) Stock Rating Upgraded by Wall Street ZenWall Street Zen upgraded Jasper Therapeutics from a sell to a hold rating. The stock has an average analyst rating of Hold with a consensus price target of $7.33. The company reported a loss of $0.10 per share for the quarter, beating the consensus estimate.